

Cuba

Learning Forum: Experiences of Introducing New Vaccine in middle-income countries

Geneva, Switzerland, 23-25 April 2024

Coverage & Key Indicators			
	HPV	Rotavirus	PCV
Introduction status	Not introduced	Not applicable	Nationwide introduction approved, implementation pending
If no, or pilot, please indicate the date when the vaccine is going to be introduced or extended nationwide.	2024	Not foreseen	2024
For HPV:			
Target group: age and gender	9-year-old girls		
Delivery method: Center, School, Mixed	Mixed, but primarily schools		
Dose regimen: current and annual if change to single dose is planned	Single dose		
Key Challenges and Strategies			
Achievements/Strengths	 Single public health system. Universal and free coverage. Great human resources competence 		
Challenges	 Lack of information or inaccurate perception of health professionals and general population regarding the benefits and safety of the vaccine. Lack of knowledge and support from the education sector regarding the incorporation of this vaccine as part of school vaccination. Limited storage and conservation capacity for the new vaccine. 		
Partner support	 GAVI: Technical support with training on the characteristics, benefits and importance of vaccines. Financial support for IPV and PCV vaccine procurement and introduction activities. PAHO: assistance provided to the country in all introduction activities. 		
Gaps	• We believe that the support provided and the activities foreseen in the introduction plan to mitigate the main challenges are sufficient to ensure that all gaps are closed.		
Possible strategies	 Printing educational materials to provide more information on the benefits and safety of the new vaccine. Designing and executing a mass communication strategy (TV, radio, media, etc.) regarding the introduction of the vaccine, dosage, benefits, among others. Conducting training workshops on HPV for the education sector. Increasing the capacity and safety of the cold chain by acquiring PQS refrigerators. 		



